527 related articles for article (PubMed ID: 30667343)
21. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
[TBL] [Abstract][Full Text] [Related]
22. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
23. Revealing diverse alternative splicing variants of the highly homologous SMN1 and SMN2 genes by targeted long-read sequencing.
Dai M; Xu Y; Sun Y; Xiao B; Ying X; Liu Y; Jiang W; Zhang J; Liu X; Ji X
Mol Genet Genomics; 2022 Jul; 297(4):1039-1048. PubMed ID: 35612622
[TBL] [Abstract][Full Text] [Related]
24. Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA.
Konieczny P; Artero R
FASEB J; 2020 Feb; 34(2):3021-3036. PubMed ID: 31909520
[TBL] [Abstract][Full Text] [Related]
25. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
26. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.
Baughan TD; Dickson A; Osman EY; Lorson CL
Hum Mol Genet; 2009 May; 18(9):1600-11. PubMed ID: 19228773
[TBL] [Abstract][Full Text] [Related]
27. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing.
Coady TH; Shababi M; Tullis GE; Lorson CL
Mol Ther; 2007 Aug; 15(8):1471-8. PubMed ID: 17551501
[TBL] [Abstract][Full Text] [Related]
28. High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice.
Chen YC; Chang JG; Jong YJ; Liu TY; Yuo CY
PLoS One; 2015; 10(3):e0120721. PubMed ID: 25781985
[TBL] [Abstract][Full Text] [Related]
29. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
30. Effects of Inhibitors of SLC9A-Type Sodium-Proton Exchangers on
Kanda S; Moulton E; Butchbach MER
Mol Pharmacol; 2022 Aug; 102(2):92-105. PubMed ID: 35667685
[TBL] [Abstract][Full Text] [Related]
31. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
Zhang ML; Lorson CL; Androphy EJ; Zhou J
Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
[TBL] [Abstract][Full Text] [Related]
32. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1.
Hofmann Y; Wirth B
Hum Mol Genet; 2002 Aug; 11(17):2037-49. PubMed ID: 12165565
[TBL] [Abstract][Full Text] [Related]
33. Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.
Seo J; Singh NN; Ottesen EW; Sivanesan S; Shishimorova M; Singh RN
PLoS One; 2016; 11(4):e0154390. PubMed ID: 27111068
[TBL] [Abstract][Full Text] [Related]
34. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
35. Optimization of SMN trans-splicing through the analysis of SMN introns.
Shababi M; Lorson CL
J Mol Neurosci; 2012 Mar; 46(3):459-69. PubMed ID: 21826391
[TBL] [Abstract][Full Text] [Related]
36. Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model.
Singh NN; Singh RN
RNA Biol; 2011; 8(4):600-6. PubMed ID: 21654213
[TBL] [Abstract][Full Text] [Related]
37. Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
Lai JI; Leman LJ; Ku S; Vickers CJ; Olsen CA; Montero A; Ghadiri MR; Gottesfeld JM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3289-3293. PubMed ID: 28648462
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
[TBL] [Abstract][Full Text] [Related]
39. A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype.
Gladman JT; Bebee TW; Edwards C; Wang X; Sahenk Z; Rich MM; Chandler DS
Hum Mol Genet; 2010 Nov; 19(21):4239-52. PubMed ID: 20705738
[TBL] [Abstract][Full Text] [Related]
40. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy.
Hastings ML; Berniac J; Liu YH; Abato P; Jodelka FM; Barthel L; Kumar S; Dudley C; Nelson M; Larson K; Edmonds J; Bowser T; Draper M; Higgins P; Krainer AR
Sci Transl Med; 2009 Nov; 1(5):5ra12. PubMed ID: 20161659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
